Articles tagged with Osteoporosis
Researchers found that martial arts fall exercises can reduce hip impact forces, making them safe for older adults with osteoporosis if precautions are taken. The study suggests that martial arts training could be a viable option for preventing hip fractures in this population.
A recent international study on osteoporosis in women has found that most postmenopausal women are not aware of their actual risk of debilitating bone breaks. The study, which involved over 60,000 women aged 55 and older in 10 countries, highlights the need for public education about osteoporosis risk factors and treatment.
A landmark international study found that many postmenopausal women at high risk of fractures fail to recognize their risk factors. The study highlights the need for improved education about osteoporosis risk factors and treatment to prevent debilitating fractures.
A landmark international study of over 60,000 women found that many are unaware of their risk factors for debilitating fractures, which can lead to chronic pain, reduced mobility, and increased mortality. The study emphasizes the need for improved education on osteoporosis risk factors and treatment options.
A new study has discovered that the 'vegetable lamb' plant contains substances with promise as treatments for osteoporosis. The plant's compounds blocked the formation of bone-destroying osteoclasts in up to 97% of laboratory cultures without harming other cells.
A new study led by UCSF researchers found that unusual femur fractures are extremely rare in patients with osteoporosis, even those taking bisphosphonates for extended periods. The study's findings provide context to reports of these fractures and highlight the importance of weighing treatment benefits against potential risks.
A study of nearly 1,500 patients over seven years found that vertebroplasty significantly improves back pain within hours and provides long-term pain relief. Collaboration between interventional radiologists and medical experts is crucial for the best results.
Researchers found that bisphosphonate treatments can alter the material properties of bone, potentially affecting its mechanical integrity and contributing to atypical fractures. Long-term suppression of bone remodeling may lead to brittle bone prone to fractures.
A University of Alberta study found that pharmacist interventions led to a 200% increase in patients getting further assessment and diagnosis for osteoporosis. Pharmacists can help with education and screening, addressing the silent disease that often goes undiagnosed after age 50.
Researchers at Columbia University Irving Medical Center found that inhibiting serotonin synthesis in the gut effectively cured osteoporosis in mice and rats. The compound, LP533401, prevents bone breakdown while building new bone, offering a potential treatment for millions of osteoporosis sufferers.
A Swedish study of over 3,700 grandparents and their grandsons found that men with a male relative who suffered a hip fracture had up to 5% less bone density and 4% smaller bones than those without. This reduction in bone size increases the risk of fractures threefold.
Researchers are launching a human trial of a new osteoporosis drug, PTHrP, which may increase bone density more dramatically with fewer side effects than current treatments. The study aims to compare the efficacy of PTHrP with existing FDA-approved drugs for osteoporosis treatment.
In a study, oncostatin M was found to promote bone formation by blocking the production of a protein that inhibits bone growth when signaling through leukemia inhibitory factor receptor. This indicates the existence of a pathway for stimulating bone formation independently of bone destruction.
Researchers at Queen Mary University of London have discovered fundamental differences between skull and limb bones that could lead to new osteoporosis treatments. The study found significant variations in gene activity and behavior between the two types of bone cells.
Current UK guidelines limit postmenopausal women's treatment options due to bone mass T-score criteria. Alternative therapies are available but often require stricter conditions.
A new cause of osteoporosis has been identified: a mutation in the miR-2861 precursor that blocks expression of this crucial microRNA. This microRNA promotes bone formation and its absence is linked to primary osteoporosis in humans.
Researchers have identified a microRNA (miR-2861) that regulates bone formation, and its mutation is linked to primary osteoporosis. In addition, studies on Lyme disease transmission revealed a biphasic mode of dissemination by Borrelia burgdorferi microbes within ticks.
A large-scale meta-analysis has found a clear connection between depression and reduced bone density, increasing the risk of osteoporosis. The study, conducted by Hebrew University researchers, reveals that young women are particularly at risk, especially those with clinical depression.
A Kaiser Permanente study found that aggressively managing patients at risk for osteoporosis can reduce the hip fracture rate by 25%. The study, which followed 650,000 men and women over 50 years old, found a 38% drop in hip fractures and prevented 970 hip fractures in 2007.
A recent study found that patients treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. The study also observed higher levels of calcium concentrations in the teriparatide group.
A new study reveals that people with coeliac disease are at risk of developing osteoporosis due to an immune system attack on their bone tissue. Researchers have identified a protein called osteoprotegerin as the target of this attack, leading to rapid bone destruction and severe osteoporosis.
A study published in the Journal of Bone and Joint Surgery suggests that women over 50 with a wrist fracture are less likely to be evaluated and treated for osteoporosis compared to those with hip or spine fractures. The study highlights barriers to evaluation, including clinical inertia, cost concerns, and lack of clarity on responsib...
The International Osteoporosis Foundation's Health Professional Awareness Grants support innovative projects promoting osteoporosis knowledge among clinicians and allied health professionals. Five grants were awarded to patient societies in Armenia, Austria, Bulgaria, Hungary, and Singapore for their awareness programs targeting health...
The Arthritis Foundation of India Trust has won the prestigious IOF Linda Edwards Memorial Award for its innovative campaigns to raise awareness about osteoporosis. The organization, established in 2002, has been recognized for its efforts to improve bone health and patient care across India.
The International Osteoporosis Foundation reports a growing problem of osteoporosis in Asia, with hip fracture incidence increasing 2-to 3-fold over the past 30 years. Vitamin D deficiency and low calcium intake are widespread, resulting in significant personal suffering, lost productivity, and long-term dependence.
A Loyola University Health System study found that breast cancer patients can prevent bone loss by correcting secondary causes, such as vitamin D deficiency, and using bisphosphonate osteoporosis drugs. After one year, patients with secondary causes showed stable bone mineral density.
Hip fracture rates declined by 31.8% in females and 25% in males between 1985 and 2005, with the largest decrease among individuals aged 55-64 years. The reasons for this decline are unclear, but factors such as overweight and obesity may contribute.
Researchers identify a link between high cholesterol and osteoporosis, with the immune system playing a key role in bone loss. The study found that oxidized LDL triggers an immune response, leading to excessive bone damage.
A new UCLA study reveals the immune system plays a crucial role in bone loss, with high cholesterol levels contributing to the disease. The research identifies a new approach for treating osteoporosis using immune-based therapies.
A recent study found that the type 1 cannabinoid receptor is key to bone development and osteoporosis. Cannabis may reduce bone strength in young people but protect against osteoporosis in older age.
A new study published in CMAJ found that hip and back fractures in people aged 50 and older significantly increase mortality rates. Approximately 25% of individuals who develop a hip fracture and 16% who develop a spine fracture will die within 5 years.
A recent study published in the Canadian Medical Association Journal found that approximately 25% of men and women who develop hip fractures will die within five years, as well as 16% of those with spine fractures. The study also highlights the importance of fall prevention strategies, osteoporosis medications, and rehabilitation to re...
A new study suggests that an osteoporosis medication may be saving lives by strengthening the immune system. Researchers found that while the reduction in secondary fractures accounted for only 8% of the mortality benefit, the risk of mortality was still 23% lower in patients who received the drug.
The report reveals widespread vitamin D deficiency across six regions, with severe consequences for health and fracture rates. Prevention strategies must be initiated at a national level to address the issue.
Researchers studied postmenopausal women with RA, finding that hip bone mineral density correlated with bone erosion but not spine BMD. The study suggests that inflammation may play a role in both focal erosions and osteoporosis.
A recent study published in Annals of Internal Medicine found that elderly women with hyperkyphosis, or 'dowager's hump,' are at a higher risk for premature death. The study, which analyzed data from over 610 women, suggests that the increased spinal curvature itself may be predictive of adverse health outcomes.
Researchers have identified a potential new focus for treating osteoporosis and periodontitis by inhibiting nuclear factor-kB, a master protein controlling inflammation and immunity. This balance is crucial in bone formation and resorption.
A new study provides clear protocols for clinicians to follow, updating fracture risk algorithms and creating simple tables to guide doctors. The findings suggest that repeat bone density measurements can help prognosis of fracture in patients at risk due to age and other factors.
Patients with vertebral compression fractures experience prolonged intense pain, with over two-thirds reporting severe pain one year after injury. Current treatment and advice are deemed insufficient, requiring revised approaches to improve patient outcomes.
A space experiment has shown that bone-destroying cells sense the absence of mechanical resistance and react by destroying bone. This discovery helps explain why bedridden patients and astronauts experience bone loss, providing a potential new drug target for stopping the process.
Professor Juliet Compston has received the IBMS John G. Haddad, Jr. Award for her significant contributions to clinical research in bone and mineral metabolism. Her work focuses on metabolic bone disease, osteoporosis, and the effects of glucocorticoids on bone health.
Dr. Nick Harvey received the 2009 ESCEO-IOF Alliance for Better Bone Health Young Investigator Award for his study on indices of intrauterine growth predicting postnatal development of skeletal size and volumetric density. The award recognizes outstanding research based on fetal growth measurements made between 19 and 34 weeks gestation.
A study published by the American Academy of Neurology found that people with osteoporosis are three times more likely to experience vertigo than those without. Researchers discovered a strong link between low bone density and an increased risk of inner ear disorders, which can cause dizziness.
Dr. Roger Zebazé's project will investigate the structural causes of childhood fractures, aiming to understand bone fragility and devise preventative measures. The IOF-Servier Young Investigator Research Grant provides €40,000 support for innovative osteoporosis research.
Professor Jean-Yves Reginster, a renowned researcher and former IOF General Secretary, has been honored with the Pierre Delmas Award. He is being recognized for his significant contributions to the advancement of osteoporosis research.
Professor Ego Seeman received the IOF Medal of Achievement for his outstanding scientific contributions to osteoporosis research. The award recognizes individuals who have significantly advanced the field of osteoporosis through their original and outstanding work.
Researchers at McGill University Health Centre discover a new pathway that controls bone remodelling with interferon gamma. Interferon gamma may become an efficient drug-target for treating osteoporosis.
Researchers at Rice University have discovered a genetic mutation in rats that links to cardiovascular disease, osteoporosis, and potentially Alzheimer's disease. The study found that the mutation also increases susceptibility to arterial calcification.
A new study published in JAMA found that osteoporotic fractures can double or triple mortality rates for up to 5-10 years after the fracture. The risk is particularly high for hip fractures in women and men over 75, with a nearly threefold increase in mortality.
A new method for determining osteoporosis treatment targets has been developed using the WHO's fracture risk assessment tool, FRAX¹. This approach considers both fracture risk and cost-effectiveness to provide more accurate and targeted treatment.
Researchers found excellent agreement between CT colonography's bone density measurements and DEXA results, identifying osteoporotic bones in patients. CT colonography may be a cost-effective way to screen more people for osteoporosis without additional radiation.
Researchers at Columbia University discovered that gut serotonin plays a crucial role in bone formation, challenging the long-held belief that the skeleton controls bone growth. The study found that inhibiting serotonin release can increase bone mass and potentially treat osteoporosis.
Medicare's funding cut for dual-energy X-ray absorptiometry (DXA) may discontinue critical health services for osteoporosis patients. The test is essential for identifying those at risk and monitoring bone health, potentially leading to increased fractures and costs.
A five-year study tracked over 625,000 patients in Southern California to find that a healthy bones program reduced hip fracture rates by an average of 37.2%, with some reductions reaching as high as 50%. Implementing initiatives such as bone density tests and anti-osteoporosis medications led to significant improvements.
A study at the University of Alabama at Birmingham has identified a crucial co-receptor in parathyroid hormone signaling that selectively stimulates bone formation. This finding could lead to new osteoporosis drugs and better bone-building therapies by targeting specific cell receptors responsible for calcium uptake from the blood.
The International Osteoporosis Foundation backs the National Osteoporosis Society in criticizing NICE guidance on osteoporosis prevention and treatment. Key concerns include women's access to effective treatments, exclusion of high-risk men, and lack of incorporation of the WHO-supported Fracture Risk Assessment Tool.
Common osteoporosis medications bisphosphonates may cause irregular heartbeats and serious atrial fibrillation in patients. The risk is significant, with up to two times more likelihood of serious AF compared to placebo, highlighting the need for caution when prescribing these medications.
Researchers found that heart failure patients have a fourfold higher risk of fracture and six times the risk of hip fracture compared to other heart patients. Heart failure and osteoporosis share common risk factors such as older age, female sex, smoking, and type-2 diabetes.
Research from the Norwegian Institute of Public Health reveals that low weight among middle-aged men increases the risk of osteoporosis and fracture. Conversely, stable weight is recommended for optimal bone health. The study found that weight loss, rather than gain, was linked to increased osteoporosis risk.
A Phase IIB study demonstrated dose-dependent increases in bone mineral density (BMD) at the total hip, lumbar spine, and femoral neck fracture sites in postmenopausal women with low BMD. Odanacatib selectively inhibits cathepsin K, a key enzyme in osteoclastic bone resorption.